Insider Selling: USANA Health Sciences, Inc. (NYSE:USNA) Insider Sells 3,515 Shares of Stock

Key Points

• Insider Selling: USANA Health Sciences insider David Mulham sold 3,515 shares at an average price of $30.26, totaling over $106,000, which represents a 27.51% decrease in their ownership position.
• Strong Earnings: For the quarter ending July 22, USANA reported an EPS of $0.74, exceeding expectations of $0.54, with revenues of $235.85 million surpassing the anticipated $225.20 million.
• Analyst Upgrade: Wall Street Zen has upgraded USANA Health Sciences from a "hold" to a "buy" rating, reflecting positive sentiment among analysts regarding the company's future performance.

USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) insider David Mulham Mulham sold 3,515 shares of the stock in a transaction dated Wednesday, July 30th. The stock was sold at an average price of $30.26, for a total transaction of $106,363.90. Following the sale, the insider owned 9,260 shares of the company's stock, valued at $280,207.60. This trade represents a 27.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

USANA Health Sciences Stock Performance

USNA traded down $0.04 during midday trading on Thursday, hitting $29.48. The company had a trading volume of 80,934 shares, compared to its average volume of 183,847. USANA Health Sciences, Inc. has a twelve month low of $23.10 and a twelve month high of $45.86. The firm's 50-day simple moving average is $30.93 and its 200-day simple moving average is $30.01. The company has a market capitalization of $548.92 million, a PE ratio of 16.38, a P/E/G ratio of 0.96 and a beta of 0.64.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.54 by $0.20. USANA Health Sciences had a net margin of 3.79% and a return on equity of 9.48%. The company had revenue of $235.85 million during the quarter, compared to analysts' expectations of $225.20 million. As a group, sell-side analysts anticipate that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.

Institutional Investors Weigh In On USANA Health Sciences

Several institutional investors have recently modified their holdings of USNA. Pzena Investment Management LLC grew its position in shares of USANA Health Sciences by 9.4% during the 2nd quarter. Pzena Investment Management LLC now owns 1,198,260 shares of the company's stock worth $36,583,000 after buying an additional 103,074 shares during the period. Jacobs Levy Equity Management Inc. grew its position in shares of USANA Health Sciences by 46.2% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 188,511 shares of the company's stock worth $5,084,000 after buying an additional 59,535 shares during the period. Dimensional Fund Advisors LP grew its position in shares of USANA Health Sciences by 7.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company's stock worth $27,751,000 after buying an additional 55,059 shares during the period. Nuveen LLC acquired a new stake in shares of USANA Health Sciences during the 1st quarter worth approximately $895,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in USANA Health Sciences by 23.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 173,997 shares of the company's stock worth $4,693,000 after acquiring an additional 33,141 shares during the last quarter. Institutional investors and hedge funds own 54.25% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of USANA Health Sciences from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.